title: Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers?
authors.affiliation: Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: Hampig Raphael
authors.initials: HR
authors.lastname: Kourie
authors.affiliation: Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: Ahmad Hussein
authors.initials: AH
authors.lastname: Awada
mesh_terms: D019468:Disease Management; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000473:pathology* / Q000628:therapy*; D016609:Neoplasms, Second Primary / Q000473:pathology* / Q000628:therapy*; D059039:Standard of Care
keywords: checkpoint inhibitors; immunotherapy; metachronous cancer; synchronous cancer